Core Viewpoint - Adobe announced the discontinuation of its 25-year-old Animate animation tool, which was met with significant backlash from users, leading to a rapid reversal of the decision and highlighting the company's aggressive pivot towards AI products while neglecting user needs [1]. Group 1: Announcement and User Reaction - On February 2, Adobe declared it would shut down Animate, ceasing sales on March 1, with support for regular users until 2027 and enterprise users until 2029, without a direct replacement [1] - The decision sparked outrage among users who feared losing years of work and experience, criticizing Adobe for prioritizing AI over user needs and calling for the software to be open-sourced [1]. Group 2: Reversal of Decision - Following the user protests, Adobe quickly retracted its shutdown plan on February 4, confirming that Animate would continue to serve both new and existing users, providing technical support and security updates, but would not develop new features [1]. - This incident underscores the importance of user feedback in corporate decision-making, as Adobe's initial plan was ultimately abandoned due to the strong collective response from its user base [1].

生成式AI 一、OpenAI推桌面版Codex，多智能体并行迎战Claude Code 1. OpenAI发布macOS桌面版Codex应用，定位为"AI智能体指挥中心"，支持多Agent并行工作，通过"工作树"模式 隔离不同任务的代码变更； 2. 应用支持异步后台运行、技能系统和定时自动化任务，内置沙箱控制精确管理AI权限，CEO称"仅凭Codex就完成 了一个完整项目"； 3. OpenAI同时为所有付费用户临时加倍速率限制两个月，首次向免费用户开放Codex访问权限，正面迎战Anthropic 和Cursor。 https://mp.weixin.qq.com/s/kxXdPFtVzcxP0sLI2dcvYA 二、智谱发布GLM-OCR，0.9B参数登顶SOTA搞定复杂文档 1. 智谱发布并开源GLM-OCR模型，仅0.9B参数在OmniDocBench V1.5以94.6分登顶SOTA，性能接近Gemini-3- Pro； 2. 模型专攻手写体、复杂表格、代码文档及印章等高难场景，支持vLLM、SGLang和Ollama部署，API价格仅0.2 元/百万Tokens； 3. 技术上采用自研CogViT ...

来源：环球网 【环球网科技综合报道】2月3日消息，据The Verge报道，Adobe将于2026年3月1日停止开发其经典2D 动画软件Animate，并计划在2027年3月1日（企业客户至2029年3月1日）彻底关闭文件访问权限。 据悉，Animate（前身为Flash Professional）自1996年推出以来，曾主导互联网动画时代，并成为全球动 画教育、独立游戏开发和短视频内容创作的核心工具。Adobe在声明中承认，Animate"在构建动画生态 系统中发挥了关键作用"，但声称"技术进步催生了更符合用户需求的新平台"。 然而，Adobe未能提供直接替代产品，仅建议用户通过其他Creative Cloud工具"部分实现功能"。 Adobe的决策与其激进的AI战略直接相关。近年来，该公司推出了Firefly AI订阅服务，生成图像/视频 功能。此外，为企业客户定制生成式AI模型，并将AI集成至Photoshop、Express等核心产品。财报显 示，Adobe AI相关收入占比已超30%，但其代价是牺牲传统工具线。此前，该公司已停更Flash Player、 淘汰传统型设计软件，此次Animate的退出 ...

Core Insights - Phibro Animal Health (PAHC) shares have increased by 59.6% this year, significantly outperforming the industry and the S&P 500 [1][2] Company Performance - The company holds a Zacks Rank 1 (Strong Buy) and is benefiting from the strong performance of its Animal Health portfolio, particularly in vaccines and emerging markets [2][4] - Phibro markets around 800 product lines across approximately 90 countries, focusing on food and companion animals, and is expanding its product offerings in the companion animal sector [3][4] Revenue Growth - The surge in share price is attributed to strong traction in the Animal Health business, with medicated feed additives (MFA) revenues growing by 81% in Q1 of fiscal 2026, bolstered by the integration of Zoetis' MFA business [4][9] - Vaccine sales increased by 25% year over year in Q1 of fiscal 2026, with management identifying vaccines as a key growth driver [5][9] Global Expansion - Phibro's sales in Europe, the Middle East, and Africa rose by 44.4%, while Asia Pacific sales surged by 101.1% in Q1 of fiscal 2026, reflecting the company's successful global expansion strategy [6][9] Financial Estimates - The Zacks Consensus Estimate predicts a 32.1% increase in earnings per share (EPS) for fiscal 2026, reaching $2.76, and a 6.2% increase for fiscal 2027, reaching $2.93 [11] - Revenues for fiscal 2026 are projected to grow by 13.1% to $1.47 billion, with fiscal 2027 revenues expected to reach $1.51 billion, indicating a 2.8% increase [11]

Core Insights - Phibro Animal Health (PAHC) shares have increased by 82.1% this year, significantly outperforming the industry growth of 5.3% and the S&P 500 Composite's gain of 14.2% [1] - The company holds a Zacks Rank 2 (Buy) and is benefiting from a strong Animal Health portfolio, particularly in vaccines and international market expansion [1] Company Overview - Phibro operates approximately 800 product lines across 90 countries, focusing on food and companion animals, including poultry, swine, and cattle, while also producing ingredients for various industries [2] - The company is currently emphasizing the livestock sector but is also investing in the companion animal market [2] Performance Drivers - The surge in PAHC's share price is attributed to robust growth in its Animal Health business, with key products like medicated feed additives and nutritional specialty products gaining traction [3] - The acquisition of Zoetis' MFA portfolio added over 37 established product lines and six manufacturing sites, contributing to a 77% year-over-year increase in MFA sales in Q4 of fiscal 2025 [3] - Vaccine sales rose by 21% year-over-year, driven by growth in poultry products in Latin America and increased international demand [4] Global Expansion - Phibro's operations extend to high-growth regions such as Brazil, China, India, and Southeast Asia, positioning the company to capitalize on livestock production growth [5] Financial Estimates - The Zacks Consensus Estimate projects a 22.9% increase in earnings per share (EPS) for fiscal 2026, reaching $2.57, and a 4.9% increase for fiscal 2027, reaching $2.69 [11] - Revenues for fiscal 2026 are expected to grow by 13.1% to $1.47 billion, with a slight increase to $1.49 billion projected for fiscal 2027 [11]

Core Insights - Phibro Animal Health Corporation (PAHC) experienced significant growth in its Animal Health business during the fourth quarter of fiscal 2025, driven by a recovery in Mineral Nutrition and Performance Products, although macroeconomic conditions remain a concern [1][11]. Group 1: Financial Performance - PAHC's shares have increased by 101.1% over the past year, outperforming the industry growth of 3% and the S&P 500's increase of 20.7% [2]. - The company reported a market capitalization of $1.60 billion and has consistently surpassed earnings estimates over the last four quarters, achieving an average surprise of 27.88% [2]. - The Animal Health segment saw a 53% year-over-year sales growth in Q4, with a 77% increase in medicated feed additives (MFAs) and other product sales, bolstered by the acquisition of Zoetis products and strong international demand [5][9]. Group 2: Business Segments - The Animal Health business includes key products like MFAs and nutritional specialty products, which are gaining traction in the global dairy industry [3]. - The acquisition of Zoetis added over 37 established product lines and six manufacturing sites across the U.S., Italy, and China [4]. - Nutritional specialty product net sales increased by 11%, while vaccine net sales grew by 21%, driven by poultry product growth in Latin America and increased international demand [5]. Group 3: Mineral Nutrition and Performance Products - The Mineral Nutrition segment reported a 3% increase in net sales, primarily due to higher demand for copper and trace minerals [6]. - Performance Products net sales rose by 13% year-over-year, reflecting increased demand for ingredients used in personal care products [7]. - The gross profit for Mineral Nutrition increased by $0.5 million, supported by higher average selling prices, while Performance Products gross profit rose by $0.2 million [7]. Group 4: Solvency and Economic Conditions - At the end of fiscal 2025, PAHC had $77 million in cash and only $16 million in short-term debt, indicating a strong solvency position [10]. - Macroeconomic challenges, including sanctions, supply chain disruptions, and inflationary pressures, are impacting profitability and financial performance, with a 44.5% increase in the cost of goods sold leading to a contraction in gross margin [11][12]. Group 5: Future Estimates - The Zacks Consensus Estimate for fiscal 2026 earnings per share (EPS) has increased by 6.5% to $2.45, with revenue estimates at $1.46 billion, reflecting a 12.9% rise from the previous year [13].

Core Insights - Phibro Animal Health Corporation (PAHC) is focusing on advancing its Animal Health business, which is expected to drive growth in the upcoming quarters [1] - The company has shown strong performance with a 39.9% increase in shares over the past year, significantly outperforming the industry and S&P 500 [2] - Recovery in Mineral Nutrition and Performance Products is contributing to overall growth, although macroeconomic conditions remain a concern [1][9] Animal Health Business - Phibro's key animal health products, including Medicated Feed Additives (MFAs) and nutritional specialty products, are enhancing animal nutrition and are crucial for growth [3] - The Animal Health business reported a 42% sales growth year over year, with MFAs and other product sales increasing by 68% [4][8] - Nutritional specialty products saw an 8% increase in net sales, driven by improved domestic dairy demand [4] Global Market Presence - Phibro's operations outside the United States contributed approximately 40% to total revenues during the fiscal third quarter [6] - The company is targeting high-growth regions such as Brazil, China, India, and Southeast Asia, where livestock production growth rates are expected to exceed average levels [5] Mineral Nutrition and Performance Products - The Mineral Nutrition business grew 4% year over year, supported by increased sales volume and pricing [7] - Performance Products experienced a 28% year-over-year sales increase due to rising demand for personal care product ingredients [7][8] Macroeconomic Challenges - Phibro's operations are impacted by economic sanctions, supply chain disruptions, and inflationary pressures, particularly due to the ongoing conflict between Russia and Ukraine [9] - The cost of goods sold increased by 32.5% from the prior year, reflecting the adverse macroeconomic environment [9] Financial Estimates - The Zacks Consensus Estimate for fiscal 2025 earnings per share (EPS) has increased by 1.5% to $2.04, with revenue estimates at $1.28 billion, indicating a 25.6% rise from the previous year [10]